Real-world experience of vedolizumab use in Colombian patients with inflammatory bowel disease¿EXVEDOCOL Viviana Parra; Sandra Cifuentes; Sandra Avendaño; Enrique Ponce de León; Cristian Florez; Gustavo Reyes; Fabian Puentes; Manuel Ballesteros; Edilberto Nuñez; Federico Gómez; Juan Ricardo Márquez;

Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn¿s Disease and Ulcerative Colitis Francisco Rodríguez-Moranta; Federico Argüelles-Arias; Joaquín Hinojosa del Val; Marisa Iborra Colomino; M. Dolores Martín-Arranz; Luis Menchén Viso; Fernando Muñoz Núñez; Elena Ricart Gómez; José Germán Sánchez-Hernández; Teresa Valdés-Delgado; Jordi Guardiola Capón; Manuel Barreiro-de Acosta; Míriam Mañosa Ciria; Yamile Zabana Abdo; Ana Gutiérrez Casbas;

High persistence rate at one year- follow-up of subcutaneous vedolizumab at standard dose after switching endovenous vedolizumab, even in those previously intensified: Results of a Spanish multicentre observational study Laura Andrés; Marisa Iborra; Raquel Vicente; Lara Arias; Pilar Nos; Ana Royo-Esteban; Beatriz Sicilia;